BIOTECH MONEY MACHINE ROLLS ON  – BIOTECH BULL

BIOTECH MONEY MACHINE ROLLS ON  – BIOTECH BULL

Breakthrough Drug – Shows Great Promise NASDAQ SPEX

The BIOTECH index – XBI – has formed a solid bottom. We expect a test at the upper resistance levels of $90 and $95 respectively with the all time high being $100 .

Biotech stocks are cheap . Record numbers of biotech companies have come public and a record dollar amount raised . The industry is segmented into small sectors. From drug therapy to gene therapy. Accelerated FDA approvals have hastened successes  .  Penny Stocks News 

It is now time for serious investors to step into biotech at bargain prices at bargain these levels

Investors should take a hard look at NASDAQ SPEX  – Spherix  Inc – Read Report 

XBI Index

Next biotech wave coming soon – The future is bright for some companies

With scientific advances and accelerated FDA approvals, biotechs are tapping the market at early stages of development

Biotech IPOs are on track for a near-record year, with a crop of offerings that are younger, more highly valued—and some say riskier than any in recent memory. Stock Watch

Driven by swift advances in medical science and an accommodative Food and Drug Administration that is increasingly willing to accelerate approval of innovative drugs, biotechnology companies are tapping the public markets at very early stages of development—some even before they have a drug in a clinical trial.

Seven Articles Most Read Today

Allogene Therapeutics Inc., ALLO  founded last year, has no product revenue and is years away from getting a drug approved. Yet it raised $373 million earlier this month in one of the largest-ever initial public offerings for a biotech.

Rubius Therapeutics Inc., RUBY  in Cambridge, Mass., raised some $277 million in its July IPO, the second most of any biotech this year according to Dealogic, despite having not yet tested a drug in humans.

Homology Medicines Inc., FIXX  whose lead gene-therapy product won’t start clinical trials until 2019, raised $166 million in its March IPO—three years after its founding—and now has a market value of more than $700 million.

Overall, through mid-October, U.S.-listed IPOs for some 52 drug developers have raised $5.75 billion in gross proceeds this year, third behind $8.19 billion raised in all of 2014 and $7.06 billion raised in 2000, according to inflation-adjusted data from Dealogic.

In one of the strongest IPO markets of the past decade, some 209 companies have gone public on U.S. exchanges so far this year, raising a total of $56.6 billion, second most since 2008 on a year-to-date basis after the $88.92 billion, adjusted for inflation, raised by 249 companies in 2014, according to Dealogic.

At least six more biotechs are on deck to go public before the year is out, including NGM Biopharmaceuticals Inc., whose lead drug, to treat a type of fatty liver disease, is in midstage studies. On Wednesday, shares of Orchard Therapeutics PLC and Twist Bioscience Corp. made their public debuts after the companies raised $200 million and $70 million respectively in IPOs.

Early-stage biotechs—whose products aren’t yet tested in human clinical trials or are tested only in early Phase 1 studies—represented 37% of biotech IPOs through the third quarter of 2018 and had an average market value of $535 million, according to Ravi Mehrotra, partner at investment bank MTS Health Partners. That is up from 35% of biotech IPOs with an average market value of $471 million in 2015.

Phase 1 studies typically look only at safety, while midstage Phase 2 trials look at efficacy. Phase 3 trials, much larger and longer, are usually necessary for FDA approval but the agency has been speeding some approvals. The FDA issued 20 new drug approvals last year, including first-time approvals and approvals for new disease indications, under its accelerated approval program, up from an average of about seven annually over the previous 10 years, according to a Journal analysis of FDA data. The accelerated approval program allows drugs to come on the market before they have been definitively proven to provide a clinical benefit to patients and often before late-stage studies are completed.

Traditional drugs in later-stage development can actually take longer to gain FDA approval than some early-stage medicines, said Alexis Borisy, partner at Third Rock Ventures, a venture-capital firmbased in Boston. “The notion that a company that is pre-clinical is inferior is not correct,” he says.

Still, investors typically have sought more evidence that a drug was likely to work. And the added security of more clinical research is still valued.

Tricida Inc. of South San Francisco had completed a late-stage study at the time of its IPO, which raised $256 million in June. Chief Executive Officer Gerrit Klaerner discovered the company’s only drug, a treatment for a metabolic condition linked to kidney disease. Tricida aims to file for approval next year.

At investor meetings before the IPO, “the reception we got was, ‘Oh my God, there aren’t many companies out there with Phase 3 data,’ ” Dr. Klaerner said. Tricida shares are up 42.1% since its IPO at $19 a share.

Some industry observers caution that the quality of very early-stage entrants can be hard to judge. “You better have your eyes wide open, as this industry is as risky as it’s ever been,” said Geoff Porges, analyst at Leerink Partners LLC.

Indeed, mMany of this year’s newly public biotechs have struggled to sustain momentum past their IPOs. About 60% of the year’s new issues are trading below their offer prices, according to Dealogic and FactSet data. Of the top 20 biotechs by gross IPO proceeds this year, seven were in the red through Monday and down 31% on median from their deal price; shares in the other 13 companies were up 43% on median.

Shares in Rubius Therapeutics, which next year plans to begin clinical trials for its genetically engineered red blood cell treatments, were down 28.6% Wednesday since its IPO at $23 a share in July.

Rubius CEO Pablo Cagnoni said scientific and technology advances enable companies to tackle multiple diseases over a short span, attracting investors regardless of companies’ development stage. “Is the risk a little higher [in preclinical companies]? Perhaps,” Mr. Cagnoni said. “But some of those companies are going to be great success stories.”

Allogene is up 27.8% from its $18-a-share offer price. Co-founders Arie Belldegrun and David Chang previously ran Kite Pharma Inc., whose genetically engineered cell therapies had been tested only in small clinical trials when the company went public in 2014. Kite was acquired by Gilead Sciences Inc. for $11.9 billion in October 2017.

Six months later, the former Kite executives raised $300 million to start Allogene and develop a different type of cell therapy that, if successful, could be easier to manufacture and administer to patients than the treatments they developed at Kite.

Allogene’s lead product candidate has been tested only in early-stage clinical trials so far, but Allogene could start the studies needed for FDA approval as soon as the second half of next year, the company said.

Deals like Allogene’s are “a bet on management, reputation and the board [of directors],” said Mr. Porges, the analyst. “It’s not a validation of the product or technology—that’s going to take many quarters, if not years.”

 

From Wall St Journal

 

About WallStreetResearcher.com : 

WallStreetResearcher.com is a subsidiary of Target Publishing Inc, and is a leading publisher of todays market and investment news, commentary, proprietary research and videos from seasoned journalists, analysts and contributors covering the financial markets and global economies. Leveraging our extensive distribution network and social media presence, we have cultivated a valuable audience of engaged market enthusiasts, which in turn delivers a variety of unique opportunXities for industry partnerships, corporate communications, market exposure and investment. The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility